Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer

Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricciardi, Serena, Tomao, Silverio, de Marinis, Filippo
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762436/
https://www.ncbi.nlm.nih.gov/pubmed/19851525
_version_ 1782172921254379520
author Ricciardi, Serena
Tomao, Silverio
de Marinis, Filippo
author_facet Ricciardi, Serena
Tomao, Silverio
de Marinis, Filippo
author_sort Ricciardi, Serena
collection PubMed
description Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.
format Text
id pubmed-2762436
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-27624362009-10-22 Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer Ricciardi, Serena Tomao, Silverio de Marinis, Filippo Ther Clin Risk Manag Review Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study. Dove Medical Press 2009 2009-10-12 /pmc/articles/PMC2762436/ /pubmed/19851525 Text en © 2009 Ricciardi et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Ricciardi, Serena
Tomao, Silverio
de Marinis, Filippo
Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
title Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
title_full Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
title_fullStr Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
title_full_unstemmed Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
title_short Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
title_sort pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762436/
https://www.ncbi.nlm.nih.gov/pubmed/19851525
work_keys_str_mv AT ricciardiserena pemetrexedasfirstlinetherapyfornonsquamousnonsmallcelllungcancer
AT tomaosilverio pemetrexedasfirstlinetherapyfornonsquamousnonsmallcelllungcancer
AT demarinisfilippo pemetrexedasfirstlinetherapyfornonsquamousnonsmallcelllungcancer

Ejemplares similares